Sienna Appoints Dr John Chiplin Non-Executive Director


Sienna Cancer Diagnostics Ltd is pleased to announce the appointment of Dr John Chiplin to the Board of Directors. 

Dr Chiplin is a very experienced healthcare executive and brings considerable capital markets experience to the Board.  His most recent executive position was CEO of Polynoma LLC, a US based cancer immunotherapy company, and he was formerly the founding CEO of ASX listed Arana Therapeutics Ltd prior to that company’s acquisition by Cephalon (now Teva). 

Before his appointment at Arana Dr Chiplin was head of the UK’s $300M ITI Life Science investment fund. He is currently a Non-Executive Director of ASX listed biotechnology companies Benitec Biopharma (ASX:BLT) and Cynata Therapeutics (ASX:CYP), as well as Adalta Ltd, and was recently appointed Chairman of UK AIM listed company Scancell Holdings Plc (AIM:SCLP). Dr Chiplin is also the founder and Managing Director of Newstar Ventures, an early stage investment fund.

Dr Chiplin commented "I believe Sienna's telomerase detection platform is poised to make a dramatic impact in early stage cancer detection. It is a pleasure to be joining Sienna at such a pivotal time in the Company's growth’.

Sienna’s Chairman Dr Geoff Cumming said "We are delighted to have John join the Sienna Board as the company transitions towards further commercial growth and market expansion. John’s capital markets experience will greatly assist in the Company’s future fund raising activities and potential listing aspirations".


No Very

Captcha Image

Sign up for updates